Lidocaine (GMP)

Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence^[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia^[2]. In Vitro: Lidocaine GMP (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation^[2].
Lidocaine GMP (1-10 nM; 24-72 h) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours^[2].
Lidocaine GMP (10 nM; 48 h) increases significantly the apoptotic cell rate^[2].
Lidocaine GMP (10 nM; 48 h) down-regulates Cyclin D1 and up-regulates p21 expression significantly^[2].
Lidocaine (100 μM, 200 μM, 28 d) slowed down the conduction velocity (CV) in hPSC lines^[4].
Lidocaine (0.1-2000 μM, 5 min) exhibits limited use-dependent block (UDB) in hiPSC-derived cardiomyocytes^[5].
Lidocaine (30 μM) reduces QT interval of LQTS-CMs to a normal level^[6].
In Vivo: Lidocaine GMP (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by Lidocaine GMP has slower onset and faster recovery compared with thermal nociception block^[3].